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bypass graft
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2076Improvements in DES tech-
nology led to greater safety and
efﬁcacy of the second-generation
DES platforms compared with
the standard-bearer of the ﬁrst-
generation DES, the sirolimus-
eluting Cypher (Cordis, Johnson
& Johnson, Miami, Florida) stent
in all-comers, including patients
with uLMCA lesions (7,8). On
the other hand, both durable
polymer-based DES of the second
generation, the zotarolimus-eluting
stent (ZES) (Resolute, Medtronic
CardioVascular, Santa Rosa, Cal-
ifornia) and the everolimus-eluting
stent (EES) (Xience, Abbott
Vascular Devices, Santa Clara,
California) performed similarly in
a large spectrum of coronary
patients (9,10). However, withinthe setting of randomized trials, the proportion of patients
undergoing PCI for uLMCA lesions is as low as 2%. Possible
reasons for this underrepresentation are the use of CABG
surgery as a revascularization treatment in a considerable
proportion of patients with uLMCA lesions as well as the
preferable use of a certain type of DES by the operators.
Because these patients are at high risk for restenosis, potential
differences in efﬁcacy between commercially available
second-generation DES may be of particular importance
when treating uLMCA lesions. Moreover, identiﬁcation of
the DES with the lowest risk of restenosis is of crucial
importance for optimization of a percutaneous treatment
strategy for coronary artery disease in these patients.
We therefore designed this randomized study to investi-
gate the value of second-generation DES in the treatment of
uLMCA lesions by comparing the ZES with the EES.Methods
Patient population, randomization, and treatment
protocol. In this study, we included patients older than 18
years of age with ischemic symptoms or evidence of
myocardial ischemia in the presence of 50% de novo
stenosis located in the left main stem provided that written
informed consent for participation in the study was obtained
from the patient. Exclusion criteria were ST-segment
elevation MI within <48 h of symptom onset; prior
CABG surgery; in-stent restenosis; cardiogenic shock;
malignancies or other comorbid conditions with a life
expectancy <1 year; planned staged PCI procedure within
30 days of index PCI; planned elective surgical procedure
necessitating interruption of P2Y12-receptor inhibitors
during the ﬁrst 6 months post-enrollment; known allergy to
the study medications: everolimus, zotarolimus, or cobalt
alloy; pregnancy; or previous enrollment in this trial. Thestudy was conducted in accordance with the provisions of
the Declaration of Helsinki and with the International
Conference on Harmonisation Good Clinical Practices, and
approval of the protocol was obtained from the medical
ethics committee for all participating centers.
At each participating center, allocation to treatment with
either a ZES or an EES was performed using sealed, opaque
envelopes containing a computer-generated sequence; this
occurred immediately after the decision to proceed with
PCI. Patients were allocated to the 2 treatment groups in
equal proportions, and the treatment groups were studied
concurrently. Patients were considered enrolled in the study
and eligible for the ﬁnal intention-to-treat analysis at the
time of randomization.
Immediately after the decision to perform PCI, patients
were given 325 to 500 mg aspirin intravenously and heparin
up to a total amount of 100 U/kg body weight.
Post-PCI, patients were treated with either clopidogrel 75
mg/day or prasugrel 10mg/day for at least 12months. Aspirin
80 to 200 mg daily was given indeﬁnitely along with other
cardiacmedications according to the judgment of the patient’s
physician.
The stenting technique to be used was left to the
discretion of the operators. However, use of one stent
implantation was the preferred technique for distal bifurca-
tion lesions. In case 2 stents were needed, either “culotte
stenting” or T-stenting was the recommended strategy.
Follow-up protocol, data management, study endpoints,
and deﬁnitions. Blood samples were drawn every 8 h for
the ﬁrst 24 h after randomization and daily thereafter for
analysis of cardiac markers and blood cell counts. Daily
electrocardiographic recordings were performed until
discharge. Clinical follow-up either by telephone or ofﬁce
visit was performed at 30 days and 12 months for all
patients. Repeat coronary angiography was scheduled at 6
to 9 months after enrollment in the study. Relevant data
were collected and entered into a specialized computer
database by specialized personnel of the ISA Research
Center in Munich. An events committee blinded to treat-
ment allocation adjudicated all adverse clinical events. A list
of centers and investigators participating in the ISAR-
LEFT MAIN 2 trial is available in the Online Appendix.
Baseline, post-procedural, and follow-up coronary
angiograms were digitally recorded and assessed off-line in
the quantitative angiographic core laboratory with an auto-
mated edge-detection system (CMS version 7.1, Medis
Medical Imaging Systems, Leiden, the Netherlands) by 2
independent, experienced operators unaware of the treat-
ment allocation. Quantitative analysis was performed on the
left main area, which was considered the anatomic coronary
region from the left main stem ostium to the end of the 5-
mm proximal segments of the left anterior descending
artery, left circumﬂex artery, and ramus intermedius if the
latter had a vessel size of more than 2 mm in diameter. Left
main coronary artery (LMCA) stenosis was classiﬁed as
ostial (stenosis located within 3 mm of the LMCA ostium),
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2077midshaft (stenosis located in the medial part of LMCA with
at least 3 mm of apparently nondiseased artery before
LMCA bifurcation), and distal (stenosis involving the distal
part of the LMCA and bifurcation/trifurcation with the
proximal left anterior descending artery, proximal left
circumﬂex artery, and proximal ramus intermedius if the
latter was present).
High-risk surgical candidates were considered patients
with a Parsonnet score>15 or EuroSCORE6 (11,12). The
diagnosis of MI required the presence of new signiﬁcant Q
waves on electrocardiography and/or elevation of creatine
kinase-MB isoform (or creatine kinase if the latter was not
available) to at least 2 times the upper limit of normal in no
fewer than 2 blood samples. Target lesion revascularization
(TLR) was deﬁned as any repeat PCI involving the left
main area or CABG surgery involving at least one of the
main left coronary vessels due to luminal renarrowing in the
presence of symptoms or objective signs of ischemia. Stent
thrombosis was deﬁned according to Academic Research
Consortium criteria (13). Angiographic binary restenosis
was deﬁned as diameter stenosis 50%, measured by
quantitative coronary angiography, in the left main area.
The primary endpoint of the study was the combined
incidence of all-cause death, MI, and TLR at 1 year after
randomization. Secondary endpoints were deﬁnite or prob-
able stent thrombosis at 1 year and the incidence of binary
angiographic restenosis at follow-up angiography in the
LMCA area.
Calculation of sample size and statistical methods. To
calculate the sample size, we anticipated a 25% incidence of
the primary endpoint in both groups. Setting the non-
inferiority margin at 9%, for a power of 80% and an a level
of 0.05, 287 patients in each group were needed. Calculation
of the sample size was performed using nQuery Advisor,
Version 4.0 (Statistical Solutions, Cork, Ireland).
Two pre-speciﬁed analyses were planned to be performed
in patients with diabetes and those with high surgical risk
according to the Parsonnet score and EuroSCORE. All
analyses were planned on the basis of the intention-to-treat
principle.
Baseline descriptive statistics are presented as frequencies
and percentages for categorical variables and mean  SD or
median (interquartile range) for continuous variables. The
differences between the groups were assessed using the chi-
square test or Fisher exact test for categorical data and the
Student t test for continuous data. Survival analysis was
performed by applying the Kaplan-Meier method. Differ-
ences in survival parameters were assessed for signiﬁcance,
and relative risks (RRs) were calculated by means of the log-
rank test. Noninferiority hypothesis was formally checked
only for the primary endpoint in the overall population. In
this respect, a one-sided p value <0.05 was considered
signiﬁcant; otherwise, a 2-tailed p value <0.05 was co-
nsidered to indicate statistical signiﬁcance. Statistical soft-
ware S-PLUS, version 4.5 (S-PLUS, Insightful Corp.,
Seattle, Washington) was used for all analyses.Results
Patient population. Between December 2007 and
September 2011, 650 patients undergoing PCI for uLMCA
stenosis were enrolled and randomly assigned to receive either
a ZES or an EES at 4 tertiary centers: Deutsches Herzzen-
trum and Medizinische Klinik I, Klinikum rechts der Isar,
both in Munich, Germany; Herzzentrum in Bad Segeberg,
Germany; and the Cardiology Department at the University
of Ferrara (Ferrara, Italy). Tables 1 and 2 show the baseline,
angiographic, and procedural characteristics of the patients,
which were comparably distributed between the 2 treatment
groups. The proportion of high-risk surgical candidates was
similar in both groups, with a Parsonnet score >15 in 37.0%
of patients assigned to receive a ZES and in 35.3% of patients
assigned to receive an EES (p ¼ 0.70) and a Euro-
SCORE 6 in 43.0% and 36.8% of patients, respectively
(p ¼ 0.11). The majority of lesions were located at the distal
LMCA (83% of patients in the ZES group and 76.8% in the
EES group; p ¼ 0.13). Implantation of the assigned stent
was successful in all patients, and the predominant stenting
technique was single stenting with both the ZES and the
EES. Additional PCI of at least 1 lesion outside the LMCA
area was performed in 110 patients (34%) in the ZES group
and 97 patients (30%) in the EES group (p ¼ 0.25). The
proportion of patients discharged on prasugrel treatment was
similar in the 2 groups (2.5% in the ZES group and 3.5% in
the EES group; p ¼ 0.14).
Clinical outcomes. In both groups, the incidence of deﬁ-
nite stent thrombosis was 0.6%. In the ZES group, 2
patients (both patients with type 1 diabetes mellitus who
underwent single stenting of the LMCA lesion) experienced
stent thrombosis at days 6 and 10 after PCI. In the EES
group, 1 patient experienced stent thrombosis 2 h after PCI
and another patient did so 10 days after PCI; both were
nondiabetic patients who underwent T-stenting of the distal
LMCA lesions. All patients who underwent stent throm-
bosis were on dual antiplatelet therapy consisting of aspirin
and clopidogrel. There was only 1 case of probable stent
thrombosis in the ZES group, which consisted of 1 sudden
death at day 14 after enrollment.
Clinical follow-up at 12  1 month was performed for all
patients, and the outcomes are shown in Table 3. The inci-
dence of the primary endpoint of death, MI, and TLR, was
17.5% (95% conﬁdence interval [CI]: 13.7% to 22.1%) in the
ZES group and 14.3% (95% CI: 10.9% to 18.6%) in the EES
group. This corresponds to a difference of 3.2% with an
upper 95% CI of þ8.0%. Accordingly, the null inferiority
hypothesis for the ZES was rejected (p< 0.001). Assignment
to the ZES group was thus associated with an RR of the
primary endpoint of 1.26 (95% CI: 0.85 to 1.85) (Fig. 1B). In
addition, no differences were observed between the 2 groups
regarding the cumulative incidence of other adverse outcomes
at 30-day and 1-year follow-up (Table 3, Fig. 1A).
The primary endpoint was also analyzed in the pre-
speciﬁed subgroups of patients deﬁned by diabetes and
Table 1 Baseline Characteristics and Therapy at Discharge
Characteristics
ZES
(n ¼ 324)
EES
(n ¼ 326) p Value
Age (yrs) 69.4  10.4 70.2  9.4 0.40
Women 88 (27.2) 74 (22.7) 0.19
Arterial hypertension 221 (68.2) 228 (69.9) 0.63
Hypercholesterolemia 223 (68.8) 257 (75.8) 0.05
Diabetes mellitus 92 (28.4) 93 (28.5) 0.97
Insulin requiring 36 (11.1) 25 (7.7) 0.13
Oral drug requiring 43 (13.3) 50 (15.3) 0.45
On diet only 13 (4.0) 8 (7.7) 0.34
Current smoker 48 (14.8) 43 (13.2) 0.55
Body mass index (kg/m2) 27.3  3.9 27.4  3.9 0.77
Acute coronary syndrome 124 (38.3) 107 (32.8) 0.15
History of myocardial infarction 103 (31.8) 94 (28.8) 0.41
History of percutaneous coronary intervention 168 (51.9) 175 (53.7) 0.64
Creatinine serum level (mg/dl) 1.09  0.71 1.09  0.70 0.99
Malignancies 71 (21.9) 77 (23.6) 0.60
Parsonnet score 13.3  10.3 13.7  11.0 0.79
EuroSCORE 5.1  3.7 5.0  3.7 0.46
Therapy at hospital discharge
Statins 289 (89.2) 287 (88.0) 0.09
ACE inhibitors 257 (79.3) 242 (74.2) 0.12
AT1 receptor blockers 50 (15.4) 55 (16.9) 0.62
Beta-blockers 304 (93.4) 297 (91.1) 0.19
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting-enzyme; AT1 ¼ angiotensin II type 1; EES ¼ everolimus-eluting stent(s); ZES ¼ zotarolimus-eluting stent(s).
Mehilli et al. JACC Vol. 62, No. 22, 2013
DES for Left Main Coronary Artery Lesions December 3, 2013:2075–82
2078surgical risk status (Fig. 2). Assignment to the ZES group
was associated with an RR of the primary endpoint of
1.14 (95% CI: 0.66 to 1.96; p ¼ 0.63) among patientsTable 2 Angiographic and Procedural Characteristics
ZES
(n ¼ 324)
EES
(n ¼ 326) p Value
Left ventricular ejection
fraction (%)
52.1  11.9 53.8  11.4 0.05
Vessel size of left main
artery (mm)
3.66  0.44 3.63  0.45 0.20
Coronary artery dominance 0.95
Right 273 (84.3) 274 (84.1)
Left 31 (9.6) 30 (9.2)
Balanced 20 (6.1) 22 (6.7)
Three-vessel disease 222 (68.5) 241 (73.9) 0.13
Occluded right coronary artery 29 (8.9) 37 (11.3) 0.31
Trifurcation morphology 51 (15.7) 52 (16) 0.95
Localization of left main lesion 0.13
Ostium 32 (10.0) 43 (13.2)
Midshaft 23 (7.0) 33 (10.0)
Distal 269 (83.0) 250 (76.8)
Stenting technique 0.60
Single stenting 200 (61.8) 217 (66.6)
Crush stenting 4 (1.2) 3 (0.9)
T-stenting 23 (7.1) 18 (5.5)
Culotte stenting 97 (29.9) 88 (27.0)
Kissing balloon technique 115 (35.5) 120 (36.8) 0.73
IABP support 6 (1.9) 9 (2.8) 0.44
Values are mean  SD or n (%).
IABP ¼ intra-aortic balloon counterpulsation; other abbreviations as in Table 1.with a Parsonnet score >15 and 1.06 (95% CI: 0.62 to
1.84; p ¼ 0.82) among patients with a EuroSCORE 6.
For diabetic patients, assignment to the ZES group
resulted in an RR of the primary endpoint of 1.24 (95%
CI: 0.69 to 2.24; p ¼ 0.47), while it was associated
with an RR of death at 1 year of 1.26 (95% CI: 0.50 to
3.20; p ¼ 0.62). In addition, the cumulative incidence
of the primary endpoint among patients undergoing
the complex 2-stenting PCI technique was 22.7% com-
pared with 13.0% among patients treated with the
single-stenting technique (RR: 1.86; 95% CI: 1.26 to
2.74). No interaction between stenting techniques and
treatment effect of the 2 stent types was observed
(pfor interaction ¼ 0.14).
Angiographic restenosis. The median (interquartile range)
interval to repeat coronary angiography was 203 (193 to 226)
days. Data on follow-up angiography were available for 237
patients (73.1%) in the ZES group and 226 patients (69.3%)
in the EES group (p ¼ 0.28). The incidence of binary
angiographic restenosis (the secondary endpoint of the
study) was not signiﬁcantly different between the 2 stent
groups: 21.5% (51 of the 237 patients) in the ZES group
and 16.8% (38 of the 226 patients) in the EES group
(RR: 1.28; 95% CI: 0.86 to 1.92; p ¼ 0.24).
Discussion
Of all the randomized trials designed to compare the
relative performance of newer generations of DES, the
Table 3 Clinical Outcomes
ZES
(n ¼ 324)
EES
(n ¼ 326)
Relative Risk
(95% CI) p Value
30 days
Deﬁnite stent thrombosis 2 (0.6) 2 (0.6) 1.00 (0.14 to 7.10) >0.99
Probable stent thrombosis 1 (0.3) 0
Death 4 (1.2) 5 (1.5) 0.80 (0.22 to 3.00) 0.74
MI 5 (1.1) 3 (0.9) 1.67 (0.41 to 6.90) 0.47
Q-wave MI 3 (0.9) 0 (0.0) 0.09
Stroke 1 (0.3) 1 (0.3) 1.00 (0.06 to 16.01) >0.99
CABG surgery 1 (0.3) 0 (0.0) 0.32
Repeat PCI 0 (0.0) 1 (0.3) 0.32
TLR 1 (0.3) 1 (0.3) 1.00 (0.06 to 16.01) >0.99
Death or MI 7 (2.2) 8 (2.5) 0.88 (0.32 to 2.42) 0.80
Death or MI or stroke 7 (2.2) 9 (2.8) 0.78 (0.29 to 2.09) 0.62
Death or MI or TLR 8 (2.5) 8 (2.5) 1.00 (0.38 to 2.68) >0.99
1 year
Death 18 (5.6) 18 (5.6) 1.00 (0.52 to 1.93) 0.98
MI 9 (2.8) 4 (1.2) 2.27 (0.72 to 7.14) 0.16
Q-wave MI 3 (0.9) 0 (0.0) 0.08
Stroke 3 (0.9) 2 (0.7) 1.50 (0.25 to 8.88) 0.65
CABG surgery 3 (0.9) 2 (0.7) 1.51 (0.26 to 8.95) 0.65
Repeat PCI 33 (10.8) 27 (8.7) 1.23 (0.74 to 2.05) 0.41
TLR 36 (11.7) 29 (9.4) 1.26 (0.78 to 2.05) 0.35
Death or MI 24 (7.5) 19 (5.9) 1.28 (0.70 to 2.33) 0.42
Death or MI or stroke 26 (8.1) 21 (6.5) 1.26 (0.71 to 2.23) 0.43
Death or MI or TLR 56 (17.5) 46 (14.3) 1.26 (0.85 to 1.85) 0.25
Values are as n (%); percentages are Kaplan-Meier estimates.
CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TLR ¼ target lesion revascularization;
other abbreviations as in Table 1.
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2079ISAR-LEFT-MAIN 2 (Intracoronary Stenting and An-
giographic Results: Drug-Eluting Stents for Unprotected
Coronary Left Main Lesions 2) trial is the only one designed
to randomly compare the ZES with the EES for treatment
of uLMCA lesions. The main ﬁndings of the present study
were that both the ZES and the EES are associated with an
excellent procedural success rate and performed similarly
regarding safety and efﬁcacy in this large cohort of relatively
nonselected patients with uLMCA disease.
Less than 5% of patients in need of revascularization
present with signiﬁcant atherosclerotic changes of the left
main stem (14). Depending on the clinical presentation,
patient age, and aggregation of comorbidities as well as the
severity of atherosclerotic involvement of the coronary tree,
1-year mortality rates between 2% and 15% after revascu-
larization have been reported (5,15–19). Although nearly
two-thirds of the patients in the ISAR-LEFT-MAIN 2 trial
presented clinically with stable or biomarker negative
unstable angina, the 1-year mortality rate was 5.6% in both
groups. This is slightly higher than that observed in the
PRECOMBAT (Premier of Randomized Comparison of
Bypass Surgery versus Angioplasty Using Sirolimus-Eluting
Stent in Patients with Left Main Coronary Artery Disease)
trial (2% in PCI-treated patients and 2.7% in CABG-
treated patients) and in the SYNTAX (Synergy between
PCI with Taxus and Cardiac Surgery) left main subgroup(4.2% in PCI-treated patients and 4.4% in CABG-treated
patients) (18,19). The older age of the population enrolled
in our study (mean age of 69 years) as well as higher
aggregation of comorbidities (mean EuroSCORE of 5.1)
compared with the PRECOMBAT and SYNTAX trials
(mean age of 62 years and 65 years and mean EuroSCORE
of 2.7 and 3.9, respectively) might explain the observed
numerical differences. This highlights the fact that the risk
of death after revascularization of uLMCA disease is
strongly associated with the age and comorbidities of the
investigated population, as shown also by several publica-
tions (1,4,5,17,20).
In addition, the risk of MI in our study was 2%, which is
lower than that reported in trials using ﬁrst-generation
DES (3.5% to 5%) and comparable to that of CABG-
treated patients (2.9%), as reported in a recently published
meta-analysis of randomized trials comparing PCI and
CABG surgery in uLMCA disease (15,17,19). A growing
body of evidence demonstrates that implantation of second-
generation DES, particularly the EES, reduces the risk of
MI by up to 40% compared with ﬁrst-generation DES (21).
In particular, the reported attenuation of the risk of very late
stent thrombosis by more than 70% with the EES sounds
very promising for patients with uLMCA disease (7,21).
Thus, in our trial, which was the ﬁrst to exclusively use
second-generation DES in unselected patients with
Figure 1 1-Year Adverse Event Rates in the ZES and EES Groups
(A) Composite of death, myocardial infarction, and stroke. (B) Composite of death, myocardial infarction, and target lesion revascularization. EES ¼ everolimus-eluting stent(s);
ZES ¼ zotarolimus-eluting stent(s).
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2080uLMCA disease, the increased risk of MI at 3-year follow-
up observed with the Taxus stent in the SYNTAX LMCA
subgroup might fail to appear (3).
Despite the type of stent, the interventional strategy seems
to play a crucial role in outcomes after PCI. The majority of
LMCA lesions are located at the distal part of the left main
stem involving the bifurcation, which make their treatment
technically challenging. Single stenting is associated with
both reduction of peri-PCI MI and restenosis-driven TLR
(22–24). Different from the ﬁrst ISAR-LEFT-MAIN trial
(50%), the complex 2-stenting technique was used in 35% of
patients enrolled in the current trial. The severity of LMCA
disease, however, was more pronounced in the ISAR-
LEFT-MAIN 2 trial (80% distal lesions) as compared
with the ﬁrst one (63%). This might explain the slightlydifferent TLR rates observed: 9.4% with EES and 11.7%
with ZES versus w7% with the ﬁrst-generation DES (15).
Although the lack of difference in antirestenotic efﬁcacy
between the ZES and the EES is in accordance with
previously reported trials (9,10), the observed TLR rates are
comparable with those reported in all-comer studies with
per-protocol required follow-up angiography (25–27).
Study limitations. The lack of an additional group treated
with CABG or with a ﬁrst-generation DES obviously limits
direct comparisons with these treatment options. Importantly,
the overall incidence of major adverse cardiac events in our
study, 17.5% with the ZES and 14.3% with the EES, is
comparable to that reported after CABG surgery (7% to 25%)
or after implantation of a ﬁrst-generation DES (9% to 30%)
(15,17–19). The observed lower than expected adverse event
Figure 2
1-Year Incidence and Relative Risk of the Primary Endpoint of Death, Myocardial Infarction, and
Target Lesion Revascularization in Pre-Speciﬁed Subgroups
Relative risks associated with the use of the ZES as compared with the EES are shown with the 95% CIs. CI ¼ conﬁdence interval; other abbreviations as in Figure 1.
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2081rate in the present study negatively affects its statistical strength
by reducing its power and because the selected noninferiority
margin actually represents a larger relative proportion of the
event rate in the control group than the predeﬁned proportion
for sample size calculation. Although the large noninferiority
margin allows achievement of a realistic sample size regarding
patients with uLMCA disease, it might be problematic for
studies with clinical events as the primary endpoint. This trial
had only 57% power for a noninferiority margin of relative
reduction of 25% instead of the actual margin of 36%. It is,
however, reassuring that the actual result did not show any
relevant numeric signal to question the noninferiority of the
evaluated DES. Hitherto, this trial still remains the ﬁrst
randomized trial to compare newer generations of DES in
LMCA lesions. Furthermore, the follow-up angiography rate
of 70% might have exaggerated the TLR rates in both groups.
However, it helped us obtain information on the incidence of
binary angiographic restenosis in this high-risk population,
which was only numerically higher with the ZES (21.5%) as
compared with the EES (16.8%).
Conclusions
Within the statistical limitations of the present study, both
second-generation ZES and EES platforms provided
comparable clinical and angiographic outcomes at 1-year
follow-up when used for treatment of uLMCA lesions in
a relatively unselected population.Reprint requests and correspondence: Dr. Julinda Mehilli,
Munich University Clinic, Marchioninistrasse 15, 81377 Munich,
Germany. E-mail: julinda.mehilli@med.uni-muenchen.de.REFERENCES
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APPENDIX
For a listing of the centers and investigators who participated in the
ISAR-LEFT MAIN-2 study, please see the online version of this article.
